CN115087640A - 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途 - Google Patents

桥杂环基取代的嘧啶类化合物及其制备方法和医药用途 Download PDF

Info

Publication number
CN115087640A
CN115087640A CN202280002343.4A CN202280002343A CN115087640A CN 115087640 A CN115087640 A CN 115087640A CN 202280002343 A CN202280002343 A CN 202280002343A CN 115087640 A CN115087640 A CN 115087640A
Authority
CN
China
Prior art keywords
compound
cancer
pharmaceutically acceptable
acceptable salt
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280002343.4A
Other languages
English (en)
Inventor
殷惠军
闫旭
史记周
刘国标
董流昕
邵明召
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
National Institutes of Pharmaceutical R&D Co Ltd
Original Assignee
National Institutes of Pharmaceutical R&D Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by National Institutes of Pharmaceutical R&D Co Ltd filed Critical National Institutes of Pharmaceutical R&D Co Ltd
Publication of CN115087640A publication Critical patent/CN115087640A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

桥杂环基取代的嘧啶类化合物及其制备方法和医药用途。所述化合物或包含其的药物组合物可以作为JAK1和TYK2激酶抑制剂，用于治疗与JAK1和TYK2激酶活性相关的疾病，例如炎症、自身免疫性病症、癌症等。

Description

PCT国内申请，说明书已公开。

Claims (9)

  1. PCT国内申请，权利要求书已公开。
CN202280002343.4A 2021-01-14 2022-01-12 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途 Pending CN115087640A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110048366 2021-01-14
CN2021100483666 2021-01-14
PCT/CN2022/071491 WO2022152140A1 (zh) 2021-01-14 2022-01-12 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途

Publications (1)

Publication Number Publication Date
CN115087640A true CN115087640A (zh) 2022-09-20

Family

ID=82447964

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280002343.4A Pending CN115087640A (zh) 2021-01-14 2022-01-12 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途

Country Status (9)

Country Link
US (1) US20240109890A1 (zh)
EP (1) EP4279485A1 (zh)
JP (1) JP2024502648A (zh)
KR (1) KR20230131240A (zh)
CN (1) CN115087640A (zh)
AU (1) AU2022206999A1 (zh)
CA (1) CA3204761A1 (zh)
TW (1) TW202227419A (zh)
WO (1) WO2022152140A1 (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074867A (zh) * 2014-08-21 2017-08-18 辉瑞公司 作为jak抑制剂的氨基嘧啶基化合物
CN110862376A (zh) * 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 一种小分子化合物
WO2021027647A1 (zh) * 2019-08-09 2021-02-18 中国医药研究开发中心有限公司 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113372351A (zh) * 2020-03-10 2021-09-10 明慧医药（杭州）有限公司 一类jak激酶抑制剂及其制备和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107074867A (zh) * 2014-08-21 2017-08-18 辉瑞公司 作为jak抑制剂的氨基嘧啶基化合物
WO2021027647A1 (zh) * 2019-08-09 2021-02-18 中国医药研究开发中心有限公司 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
CN110862376A (zh) * 2019-10-24 2020-03-06 嘉兴特科罗生物科技有限公司 一种小分子化合物

Also Published As

Publication number Publication date
AU2022206999A1 (en) 2023-07-13
TW202227419A (zh) 2022-07-16
JP2024502648A (ja) 2024-01-22
US20240109890A1 (en) 2024-04-04
EP4279485A1 (en) 2023-11-22
CA3204761A1 (en) 2022-07-21
KR20230131240A (ko) 2023-09-12
WO2022152140A1 (zh) 2022-07-21

Similar Documents

Publication Publication Date Title
CN107759587B (zh) [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CN107428758B (zh) 丙烯酸类衍生物、其制备方法及其在医药上的用途
CN109415361B (zh) 丙烯酸类衍生物及其制备方法和其在医药上的用途
EP3786167A1 (en) Diaryl macrocyclic compound and pharmaceutical composition, and use thereof
CN111712491B (zh) 四氢异喹啉类化合物、其制备方法、包含此类化合物的药物组合物及其用途
CN113980014B (zh) 氢化吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用
US10501466B2 (en) WDR5 inhibitors and modulators
JP2021513519A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
JP2020530451A (ja) ムスカリン性アセチルコリン受容体ｍ４のアンタゴニスト
EP4186905A1 (en) Compound serving as btk inhibitor, preparation method therefor, and use thereof
JP2017504632A (ja) ２−（ｔｅｒｔ−ブチルアミノ）−４−（（１Ｒ，３Ｒ，４Ｒ）−３−ヒドロキシ−４−メチルシクロヘキシルアミノ）−ピリミジン−５−カルボキサミドの固体形態、その組成物、及びその使用方法
TW202035422A (zh) 作為ｃｄｋ抑制劑的大環化合物、其製備方法及其在醫藥上的應用
EP3865487A1 (en) Aromatic ring-linked dioxane-quinazoline or -quinoline compounds, compositions and use thereof
WO2020077361A1 (en) Compounds and methods of their use
CN107880038B (zh) [1,2,4]三唑并[1,5-a]吡啶类化合物及其制备方法和医药用途
CN115087640A (zh) 桥杂环基取代的嘧啶类化合物及其制备方法和医药用途
CN115611877A (zh) 磺酰胺类化合物、其制备方法及其在医药上的应用
EP3697786B1 (en) Substituted pyrrolopyridines as inhibitors of activin receptor-like kinase
CN109206435B (zh) 噻吩并[3,2-d]嘧啶类化合物及其制备方法和医药用途
TWI828289B (zh) 作為tyk2/jak1假激酶結構域抑制劑的化合物及合成和使用方法
CN111116572A (zh) 噁二唑衍生物及其制备方法和用途
CN112209933B (zh) 含有4-氮杂螺庚烷的btk抑制剂
CN113993871B (zh) 含有5-氮杂螺庚烷的btk抑制剂
WO2021219140A1 (zh) 一种jak2抑制剂及其应用
WO2023143384A1 (zh) 一种抑制或降解hpk1激酶的化合物及其在医药中的用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40072728

Country of ref document: HK